Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Once-weekly Subcutaneous Administration of Bortezomib in Patients with Multiple Myeloma

  • Wang, Liang (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Wang, Ke-Feng (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Chang, Bo-Yang (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Chen, Xiao-Qin (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) ;
  • Xia, Zhong-Jun (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
  • Published : 2015.03.18
Download PDF
⟨ Previous Next ⟩

Abstract

In patients with multiple myeloma (MM), once-weekly intravenous injection or twice-weekly subcutaneous injection (SC) of bortezomib has been proven to offer non-inferior efficacy to standard twice-weekly intravenous administration, with an improved safety profile. However, whether once-weekly SC bortezomib can further reduce the incidence rate of peripheral neuropathy (PN) and not compromise the efficacy remains to be investigated. 25 patients of MM treated with once-weekly SC bortezomib were reviewed in this study. The median treatment cycles were 4 (range, 2-9 cycles). Complete response (CR) rate was 52%, ${\geq}$very good partial response (VGPR) rate was 72%, and ${\geq}$partial response (PR) rate was 84%. 1-year and 2-year PFS rate was 63.0% and 34.3%, respectively, and 2-year OS rate was 100%. Any grade of PN was reported in 9 patients (36.0%), with 7 patients (28.0%) had grade 1 PN, and 2 patients (8.0%) had grade 2 PN. No patients reported grade 3/4 PN in this cohort. In conclusion, once-weekly subcutaneous administration of bortezomib offers excellent efficacy with a further improved safety profile, especially with regard to PN. It needs to be validated in future prospective randomized trials.

Keywords

References

  1. Avet-Loiseau H, Leleu X, Roussel M, et al (2010). Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol, 28, 4630-4. https://doi.org/10.1200/JCO.2010.28.3945
  2. Badros A, Goloubeva O, Dalal J S, et al (2007). Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 110, 1042-9. https://doi.org/10.1002/cncr.22921
  3. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF (2013). Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood, 121, 884-92. https://doi.org/10.1182/blood-2012-05-432203
  4. Bringhen S, Larocca A, Rossi D, et al (2010). Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 116, 4745-53. https://doi.org/10.1182/blood-2010-07-294983
  5. Chanan-Khan A A, and Giralt S (2010). Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol, 28, 2612-24. https://doi.org/10.1200/JCO.2009.25.4250
  6. Durie B G, Harousseau J L, Miguel J S, et al (2006). International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-73. https://doi.org/10.1038/sj.leu.2404284
  7. Engelhardt M, Kleber M, Udi J, et al (2010). Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma, 51, 1424-43. https://doi.org/10.3109/10428194.2010.487959
  8. Harousseau J L, Attal M, and Avet-Loiseau H (2009). The role of complete response in multiple myeloma. Blood, 114, 3139-46. https://doi.org/10.1182/blood-2009-03-201053
  9. Kapoor P, Kumar S K, Dispenzieri A, et al (2013). Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol, 31, 4529-35. https://doi.org/10.1200/JCO.2013.49.0086
  10. Knopf KB, Duh MS, Lafeuille MH, et al (2014). Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk, 14, 380-8. https://doi.org/10.1016/j.clml.2014.03.005
  11. Koh Y, Lee S Y, Kim I, et al (2014). Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol, 74, 653-7. https://doi.org/10.1007/s00280-014-2555-0
  12. Kumar SK, Rajkumar SV, Dispenzieri A, et al (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-20. https://doi.org/10.1182/blood-2007-10-116129
  13. Lu J, Lu J, Chen W, et al (2014). Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J, 4, 239. https://doi.org/10.1038/bcj.2014.55
  14. Mateos M V (2010). Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev, 36, 24-32. https://doi.org/10.1016/j.ctrv.2009.09.003
  15. Moreau P, Pylypenko H, Grosicki S, et al (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol, 12, 431-40. https://doi.org/10.1016/S1470-2045(11)70081-X
  16. Morgan GJ (2013). Transplants for the elderly in myeloma. Blood, 122, 1332-4. https://doi.org/10.1182/blood-2013-07-510941
  17. Nooka AK, Kaufman JL, Behera M, et al (2013). Bortezomibcontaining induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer, 119, 4119-28. https://doi.org/10.1002/cncr.28325
  18. Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson K C (2009). Multiple myeloma. Lancet, 374, 324-39. https://doi.org/10.1016/S0140-6736(09)60221-X
  19. Reeder CB, Reece DE, Kukreti V, et al (2010). Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-7. https://doi.org/10.1182/blood-2010-02-271676
  20. Richardson PG, Briemberg H, Jagannath S, et al (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 24, 3113-20. https://doi.org/10.1200/JCO.2005.04.7779
  21. Richardson PG, Delforge M, Beksac M, et al (2012). Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 26, 595-608. https://doi.org/10.1038/leu.2011.346
  22. Roschewski M, Korde N, Wu SP and Landgren O (2013). Pursuing the curative blueprint for early myeloma. Blood, 122, 486-90. https://doi.org/10.1182/blood-2013-01-481291
  23. Sonneveld P, Goldschmidt H, Rosinol L, et al (2013). Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol, 31, 3279-87. https://doi.org/10.1200/JCO.2012.48.4626
  24. Sonneveld P, Schmidt-Wolf I G, van der Holt B, et al (2012). Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol, 30, 2946-55. https://doi.org/10.1200/JCO.2011.39.6820
  25. Voorhees P M, Laubach J, Anderson K C and Richardson P G (2013). Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood, 121, 858. https://doi.org/10.1182/blood-2012-11-465765
  26. Wang A, Duan Q, Liu X, et al (2012). (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/ thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol, 91, 1779-84. https://doi.org/10.1007/s00277-012-1520-4

Cited by

  1. Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1833
  2. International Scoring System in Symptomatic Multiple Myeloma: Experience from a Tertiary Care Center vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2031
  3. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis vol.12, pp.3, 2017, https://doi.org/10.1371/journal.pone.0172996
  4. Proteasome-associated deubiquitinases and cancer pp.1573-7233, 2017, https://doi.org/10.1007/s10555-017-9697-6